San Diego-centered Viking Therapeutics marked itself as a serious competitor within the weight loss drug market in February just after revealing promising information from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the company u